<DOC>
	<DOCNO>NCT00611793</DOCNO>
	<brief_summary>PTK787/ZK222584 orally active inhibitor VEGF-R tyrosine kinase . Bevacizumab intravenous humanize monoclonal antibody direct vascular endothelial growth factor . By bind VEGF , bevacizumab block VEGF-A receptor binding . Due different mechanism action non-overlapping toxicity profile two agent , hop combination regimen incorporate compound produce increased activity without enhanced toxicity .</brief_summary>
	<brief_title>PTK787/ZK222584 With Bevacizumab Patients With Refractory and/or Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Histologically proven advanced solid tumor resistant standard treatment and/or know effective therapy Age ≥ 18 year old ECOG Performance Status 0 1 Laboratory value ≤ 7 day prior treatment : Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L ( ≥ 1500/mm3 ) Platelets ( PLT ) ≥ 100 x 109/L ( ≥ 100,000/mm3 ) Hemoglobin ( Hgb ) ≥ 9 g/dL Serum creatinine ≤ 1.5 ULN Serum bilirubin ≤ 1.5 ULN International Normalized Ratio ( INR ) &lt; 2.0 Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤ 3.0 x ULN Negative proteinuria base dip stick reading OR , documentation +1 result protein dip stick reading , total urinary protein ≤ 500 mg measure creatinine clearance ( CrCl ) ≥ 50 mL/min 24hour urine collection Life expectancy ≥ 12 week Written inform consent obtain accord local guideline History presence central nervous system ( CNS ) disease ( i.e. , primary brain tumor , malignant seizure , CNS metastases carcinomatous meningitis ) Patients history another primary malignancy ≤ 5 year , exception inactive basal squamous cell carcinoma skin Prior chemotherapy ≤ 3 week prior registration and/or randomization . Patients must recover therapyrelated toxicity Prior biologic immunotherapy ≤ 2 week prior registration and/or randomization . Patients must recover therapyrelated toxicity Prior full field radiotherapy ≤ 4 week limited field radiotherapy ≤ 2 week prior randomization . Patients must recover therapyrelated toxicity . The site previous radiotherapy evidence progressive disease site disease Major surgery ( i.e. , laparotomy ) ≤ 4 week prior randomization . Minor surgery ≤ 2 week prior randomization . Insertion vascular access device consider major minor surgery regard . Patients must recover surgeryrelated toxicity Patients receive investigational drug ≤ 4 week prior registration and/or randomization Prior therapy antiVEGF agent ( include PTK787/ZK222584 bevacizumab ) Pleural effusion ascites cause respiratory compromise ( ≥ CTC grade 2 dyspnea ) Female patient pregnant breast feeding , adult reproductive potential employ effective method birth control . Barrier contraceptives must use throughout trial sex . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . Women childbearing potential must negative serum pregnancy test 48 hour prior administration study treatment . Please refer appendix 3 list example substrates human liver microsomal P450 enzymes Any follow concurrent severe and/or uncontrolled medical condition could compromise participation study : Uncontrolled high blood pressure ( &gt; 160/100 medication ) , history labile hypertension , history poor compliance antihypertensive regimen Unstable angina pectoris Symptomatic congestive heart failure Myocardial infarction ≤ 6 month prior registration Serious uncontrolled cardiac arrhythmia Uncontrolled diabetes Active uncontrolled infection Interstitial pneumonia extensive symptomatic interstitial fibrosis lung Chronic renal disease Acute chronic liver disease ( e.g. , hepatitis , cirrhosis ) Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption PTK787/ZK 222584 ( i.e. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow tablet ) Patients confirm diagnosis human immunodeficiency virus ( HIV ) infection exclude investigator 's discretion he/she feel 1 ) potential drug interaction PTK787/ZK 222584 patient 's antiHIV medication could influence efficacy antiHIV medication , 2 ) may place patient risk due pharmacologic activity PTK787/ZK 222584 . Please refer appendix 3 list example substrates human liver microsomal P450 enzymes Patients take therapeutic warfarin sodium ( Coumadin ) similar oral anticoagulant metabolize cytochrome P450 system . Heparin allow . Please refer appendix 3 list example substrates human liver microsomal P450 enzymes Patients receive chronic daily treatment aspirin ( &gt; 325 mg/day ) daily dos platelet inhibitory nonsteroidal antiinflammatory agent ( e.g . Ibuprofen 800 mg qid , naproxen 500 mg bid ) Patients receive chronic steroid therapy Any nonhealing wound , ulcer , long bone fracture Clinical history hemoptysis hematemesis within past 3 month Clinical evidence history bleed diathesis coagulopathy History stroke within 6 month Patients unwilling unable comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Refractory Malignancy</keyword>
	<keyword>Advanced Malignancies</keyword>
	<keyword>PTK787/ZK222584</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>